Octapharma Australia

Octapharma is a global leader in the development and manufacture of human protein therapies, operating as one of the largest plasma product specialists in the world. The company focuses on three core therapeutic areas: hematology, immunotherapy, and critical care. Its portfolio includes both plasma-derived products and innovative recombinant therapies, such as the first recombinant factor VIII produced from a human cell line. Octapharma Australia serves as the regional subsidiary, managing the distribution, clinical support, and regulatory affairs for these life-saving treatments within the Australian and New Zealand markets. The company maintains a strong commitment to patient safety and high-purity manufacturing processes, including solvent/detergent treatment and nanofiltration. As a family-owned enterprise, it reinvests significantly in research to expand its pipeline for rare and chronic diseases.